Microsoft Word - bwb_Current_Folio_Proxy_TMBSF_v5.docx

EXECUTIVE COMPENSATION

Outstanding Equity Awards at Fiscal Year-End The following table shows the number of equity awards outstanding as of December 31, 2020 for each of our named executive officers.

Option Awards

Stock Awards

Number of

Market Value of

Number of Securities Underlying Option

Shares or Units of Shares or Units of

Unexercised Options

Exercise

Stock That Have Not Vested (3)

Stock That Have Not Vested (4)

Exercisable Unexercisable

Price

Name

(#)

(#) —

($) Option Expiration Date $3.00 December 31, 2023 7.47 September 30, 2027

(#)

($)

Jerry J. Baack

100,000 (1) 90,000 (1) 16,250 (2) 27,500 (1) 90,000 (1) 6,750 (2) 75,000 (1) 90,000 (1) 6,250 (2)

60,000 (1) 48,750 (2)

12.92

December 6, 2029

40,536

$506,295

Mary Jayne Crocker

—

3.00 December 31, 2023 7.47 September 30, 2027

60,000 (1) 20,250 (2)

12.92

December 6, 2029

21,136

263,989

Jeffrey D. Shellberg

—

3.00 December 31, 2023 7.47 September 30, 2027

60,000 (1) 18,750 (2)

12.92

December 6, 2029

19,728

246,403

(1) Option awards vest or vested in 20% increments on the first five anniversaries of the date of grant. All outstanding unvested options are accelerated and vest in full upon a change in control of the Company or in the event of the death of a named executive officer. (2) Option awards vest or vested in 25% increments on the first four anniversaries of the date of grant. All outstanding unvested options are accelerated and vest in full upon a change in control of the Company or in the event of the death of a named executive officer. (3) Restricted stock awards and units vest in 25% increments on the first four anniversaries of the date of the grant. All outstanding unvested restricted stock awards and units are accelerated and vest in full upon an involuntary termination or a termination by the named executive officer for good reason, in each case in connection with a change in control of the Company, or in the event of the death or disability of a named executive officer. (4) The value of the unvested restricted stock awards and units is based upon the closing stock price of $12.49 as of December 31, 2020.

2021 Proxy Statement

27